Finished product reference
Phenylephrine / Zinc
Solution, Drops · Ophthalmic · 0.12 %/0.25 % · 10 mL
- List code
- 992
- Pharmacologic class
- Ophthalmic decongestant and astringent (alpha-1 adrenergic agonist plus zinc sulfate)
What it is and how it works
Phenylephrine, a sympathomimetic alpha-1 agonist, constricts conjunctival blood vessels and reduces redness, while zinc sulfate has a mild astringent action that precipitates surface proteins and reduces mucus and irritation.
Indications
Temporary relief of redness, irritation and discomfort of the eye due to minor irritants such as dust, smoke, wind, swimming or allergic conjunctivitis.
Dosage and administration (summary)
Topical ophthalmic: usually 1–2 drops into the affected eye(s) up to four times daily, for short-term use only.
Contraindications
Angle-closure glaucoma or narrow anterior chamber angle, hypersensitivity to any component, and concomitant or recent MAOI therapy.
Warnings and precautions
Prolonged or frequent use may cause rebound conjunctival hyperaemia. Use with caution in hypertension, cardiovascular disease, hyperthyroidism and diabetes. Seek medical advice if pain, visual change or redness persists for more than 72 hours; remove soft contact lenses before use.
Pregnancy
Use only if clearly needed; systemic absorption is low.
Storage and supply
Store below 25 °C, protected from light; discard within 4 weeks of opening.
Source: reference summary prepared from the EU SmPC/EPAR, BNF and WHO Model Formulary. The approved product information in Iran governs.
Reference information for professional sourcing and registration enquiries, not medical advice or a promotion. Drug information is condensed from US FDA prescribing information (public domain, via openFDA and DailyMed) and does not replace the product’s approved labelling in Iran. Availability, origin and documentation are confirmed per enquiry.
Tell us the quantity, the market and the timing.
Send the molecule or ingredient, the specification and the destination. We reply from Tehran with the questions, the documents and the next step.